NCBiotech News

Durham's BioSkryb is launching a grant program to secure a “breakthrough” in single-cell genomics using its proprietary technology, recently launched commercially as ResolveDNA.

The FDA has approved a once-daily capsule developed by Durham's BioCryst Pharmaceuticals to prevent the life-threatening attacks of swelling in people with the rare disease called hereditary angioedema, or HAE.

Eli Lilly and Durham gene editing innovator Precision Biosciences announced a research collaboration and exclusive license agreement that could potentially be worth over $2.7 billion.

Morrisville-based Locus Biosciences has signed an agreement with a global non-profit to help fund a new CRISPR Cas3 antibacterial therapy to treat recurrent urinary tract infections.

Gene therapy pioneer AskBio of Chapel Hill, supported in its early years by NCBiotech, will be acquired by Bayer AG, the German healthcare and ag conglomerate, for up to $4 billion.

The innovative California-based cancer-detection company GRAIL, Inc., which is establishing a $100 million-plus facility in Research Triangle Park, is preparing to go public.

Novartis has renamed its previously acquired AveXis gene therapy arm. It's now called Novartis Gene Therapies.

bluebird bio, a global gene therapy company with a new manufacturing facility in Durham, has unveiled positive results in clinical trials of its treatment for boys with a rare and deadly neurological disorder.

Leading life sciences magazine PharmaVoice has named three North Carolina executives to its list of the 100 most inspiring leaders in the pharmaceutical industry.

A young Boston-area gene therapy company, Beam Therapeutics, has joined a cluster of gene and cell therapy startups with plans to build an $83 million biomanufacturing facility in Durham that could employ more than 200 people over five years.